Kapil N. Bhalla

34.5k citations
382 papers · 26.2k · 5 hit papers · h-index 87

Impact in

  • Hematology top 0.05%
    • Chronic Myeloid Leukemia Treatments
    • Acute Myeloid Leukemia Research
  • Genetics top 0.1%
    • Chronic Lymphocytic Leukemia Research

Papers in

    • Histone Deacetylase Inhibitors Research 86
    • Protein Degradation and Inhibitors 73
    • Ubiquitin and proteasome pathways 33
    • Cell death mechanisms and regulation 30
    • Acute Myeloid Leukemia Research 105
    • Chronic Myeloid Leukemia Treatments 71

Kapil N. Bhalla

364 papers receiving 25.7k citations

Kapil N. Bhalla's Hit Papers

Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome–positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance 2007 · 542 citations
5420+9+19Years since publication10002.0k3.0k4.0k

Peers

Kapil N. Bhalla
Comparison fields: 5 of 159
  • Hematology 6.3k
  • Genetics 3.2k
  • Molecular Biology 16.4k
  • Oncology 5.3k
  • Cancer Research 2.0k
Replace H. Phillip Koeffler with:
H. Phillip Koeffler United States
Éric Solary France
Steven Grant United States
James A. McCubrey United States
Zeev Estrov United States
Marina Konopleva United States
Scott H. Kaufmann United States
Doriano Fabbro Switzerland
Suzanne Cory Australia
Jean‐Pierre J. Issa United States
Kapil N. Bhalla relative to H. Phillip Koeffler United States H. Phillip Koeffler's profile →
Citations per field
00.5×1.5×
H. Phillip Koeffler · 1×
Citations per year

Countries citing papers authored by Kapil N. Bhalla

Since Specialization
Citations

This map shows the geographic impact of Kapil N. Bhalla's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kapil N. Bhalla with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kapil N. Bhalla more than expected).

Fields of papers citing papers by Kapil N. Bhalla

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kapil N. Bhalla. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kapil N. Bhalla. The network helps show where Kapil N. Bhalla may publish in the future.

Co-authors

The 25 scholars most cited alongside Kapil N. Bhalla, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Kapil N. Bhalla Line = papers co-authored together Kapil N. Bhalla links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 382 papers — load more, or switch the sort, to bring in the rest.

#Work
1
Prevention of Apoptosis by Bcl-2: Release of Cytochrome c from Mitochondria Blocked
Hit paper breakdown →
19974300
2
Nilotinib in Imatinib-Resistant CML and Philadelphia Chromosome–Positive ALL
Hit paper breakdown →
2006974
3
Inhibition of Glycolysis in Cancer Cells: A Novel Strategy to Overcome Drug Resistance Associated with Mitochondrial Respiratory Defect and Hypoxia
Hit paper breakdown →
2005703
4
Inhibition of Histone Deacetylase 6 Acetylates and Disrupts the Chaperone Function of Heat Shock Protein 90
Hit paper breakdown →
2005646
5
Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome–positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance
Hit paper breakdown →
2007542
6 2003381
7 2008356
8 1998312
9 2017299
10 2009292
11 2010273
12 2004273
13 1998272
14 2009266
15 2007266
16 2006264
17 2005258
18
Taxol induces internucleosomal DNA fragmentation associated with programmed cell death in human myeloid leukemia cells.
1993251
19 2000248
20
Histone deacetylase inhibitor LAQ824 both lowers expression and promotes proteasomal degradation of Bcr-Abl and induces apoptosis of imatinib mesylate-sensitive or -refractory chronic myelogenous leukemia-blast crisis cells.
2003237

About Kapil N. Bhalla

Kapil N. Bhalla is a scholar working on Molecular Biology, Hematology, Genetics, Oncology and Cell Biology, having authored 382 papers that have together received 26.2k indexed citations. Recurring topics across this work include Acute Myeloid Leukemia Research (105 papers), Histone Deacetylase Inhibitors Research (86 papers), Protein Degradation and Inhibitors (73 papers), Chronic Myeloid Leukemia Treatments (71 papers), Chronic Lymphocytic Leukemia Research (56 papers), Ubiquitin and proteasome pathways (33 papers), Cell death mechanisms and regulation (30 papers) and Myeloproliferative Neoplasms: Diagnosis and Treatment (29 papers). The work is most often cited by research in Hematology (6.3k citations), Genetics (3.2k citations), Molecular Biology (16.4k citations), Oncology (5.3k citations) and Cancer Research (2.0k citations). Kapil N. Bhalla has collaborated with scholars based in United States, Germany and Switzerland. Frequent co-authors include Ana Maria Ibrado, Warren Fiskus, Jiyang Cai, Tsung-I Peng, Xuesong Liu, Xiaodong Wang, Jie Yang, Dean P. Jones, Peter Atadja and Ramadevi Nimmanapalli. Their work appears in journals such as Blood, Cancer Research, Journal of Clinical Oncology, Leukemia and Molecular Cancer Therapeutics.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact